24/7 Market News Snapshot 29 September, 2025 – Oncolytics Biotech, Inc. Common Shares (NASDAQ:ONCY)

September 29, 2025

DENVER, Colo., 29 September, 2025 (www.247marketnews.com) – (Nasdaq:ONCY) are discussed in this article.
Oncolytics Biotech, Inc. (Nasdaq:ONCY) has demonstrated significant market momentum, with shares opening at $1.33 and reaching $1.41, marking a 9.30% increase from the prior session’s close. This uptick, accompanied by a trading volume of 1.27 million shares, indicates heightened investor interest, suggesting a potential bullish sentiment around the company. Analysts are encouraged to observe resistance levels and broader market trends as they assess future entry points or potential retracements.

In tandem with its market performance, Oncolytics has provided a promising update on its registration-directed clinical trial for pelareorep, an innovative immunotherapy aimed at treating first-line pancreatic ductal adenocarcinoma (PDAC). The company plans to engage with the U.S. Food and Drug Administration (FDA) in mid-November 2025 to finalize trial design details. The trial will incorporate a robust three-arm structure, comparing a control group receiving gemcitabine with nab-paclitaxel against regimens including pelareorep alone or in combination with a checkpoint inhibitor (CPI). The primary endpoint will focus on overall survival, employing a statistically rigorous framework to assess the efficacy of the investigational treatments.

Recent analyses have suggested that pelareorep, when administered alongside chemotherapy, may enhance survival outcomes, indicating a two-year survival rate of 22%, significantly higher than the historical rate of 9% for chemotherapy alone.

Jared Kelly, Chief Executive Officer of Oncolytics, expressed enthusiasm about the upcoming trial, highlighting its potential to deliver pivotal data that could pave the way for regulatory approval of pelareorep as an immunotherapy for pancreatic cancer. The company remains committed to advancing pelareorep’s development and exploring strategic partnerships aimed at maximizing its therapeutic potential across various cancer indications.

Related news for (ONCY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.